Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1
Abstract
This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix 1 and Appendix 2 ). Updates are published regularly and can be found on the ASCO Publications website .
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (21)
Rahul Banerjee
Matthew C. Cheung
Sunnybrook Health Sciences Centre, Toronto, ON, Canada
Benjamin Derman
3The University of Chicago, Section of Hematology/Oncology, Department of Medicine, Chicago, United States
Hans Messersmith
American Society of Clinical Oncology (ASCO), Alexandria, VA
Samer Al Hadidi
1Myeloma, Waldenstrom’s, and Amyloidosis Program, Section of Hematologic Malignancies and Cellular Therapy, Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX
Sita Bhella
Cynthia Chmielewski
Health Tree Foundation, Trenton, NJ
Mohammad S. Ebraheem
Kuwait Cancer Control Center, Kuwait City, Kuwait
C. Todd Kennedy
Independent Patient and Research Advocate, Coto de Caza, CA
Shaji Kumar
Alan Langerak
City of Hope, Prescott, AZ
Brea Lipe
10University of Rochester Medical Center, Rochester, United States
Hira Mian
Department of Oncology, McMaster University, Hamilton, ON, Canada
Eloisa Riva
1British Hospital, Bone Marrow Transplant Unit, Montevideo, Uruguay
Rahul Seth
1SUNY Upstate Medical University, Syracuse, United States
Latha Subramanian
Anchorage Oncology Centre, Anchorage, AK
Saad Z. Usmani
Memorial Sloan Kettering Cancer Center, New York
Tanya M. Wildes
12Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE
Saurabh Zanwar
Ying Zhuo
Lisa K. Hicks
St Michael's Hospital and University of Toronto, Toronto, ON, Canada